Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +34.35%
#2 Siren Siren +31.73%
#3 OriginTrail OriginTrail +18.20%
#4 Purr Purr +17.28%
#5 龙虾 (Lobster) 龙虾 (Lobster) +12.28%
#6 Ethena Staked ENA Ethena Staked ENA +11.62%
#7 Wrapped XPL Wrapped XPL +11.23%
#8 DigiByte DigiByte +11.00%
#9 Collect on Fanable Collect on Fanable +10.98%
#10 Plasma Plasma +10.85%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.

PRTK
Rang in Aktien #21736
Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in... Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications. Their flagship therapeutic offerings include NUZYRA and SEYSARA. NUZYRA is a comprehensive, once-daily antibiotic, available in both oral and intravenous forms, prescribed for adult patients battling community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. SEYSARA, a medication derived from the tetracycline class, is specifically formulated to address moderate to severe cases of acne vulgaris. Beyond its internal development, Paratek maintains several strategic alliances. This includes licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc. The company also holds a license from Tufts University, enabling the development and commercialization of solutions for bacterial or microbial diseases. Furthermore, a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) is in place to advance NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc. to oversee the development, import, and sale of the XERAVATM product, utilized for complicated intra-abdominal infections of bacterial origin.
Aktienkurs
$2.23
Zuletzt synchronisiert: 2023-09-29
Marktkapitalisierung
$101.43M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Paratek Pharmaceuticals, Inc. (PRTK)

Kategorie

Healthcare
Preis PRTK mit Marktkapitalisierung von B
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
PRTK
$2.23
Marktkapitalisierung von Paratek Pharmaceuticals, Inc.(PRTK)
Marktkapitalisierung: $101.43M
Mit Stand August 2026 hat Paratek Pharmaceuticals, Inc. eine Marktkapitalisierung von $101.43M. Das macht Paratek Pharmaceuticals, Inc. laut unseren Daten zum 21736th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Paratek Pharmaceuticals, Inc. von 2009 bis 2026
PRTK im Vergleich zu den Top 5 der beliebtesten stocks
Preis für PRTK Vermögenswert B Marktkapitalisierung von B Ergebnisse
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$114,578 $101.43M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.211T +5,137,926.54%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$99,965.49 $101.43M
Apple Inc. Apple Inc.
AAPL
$4.547T +4,482,657.23%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$91,516.86 $101.43M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +4,103,795.24%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$78,991.67 $101.43M
Microsoft Corporation Microsoft Corporation
MSFT
$3.593T +3,542,127.48%
Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.
$61,404.14 $101.43M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.793T +2,753,449.00%